CRISPR makes prostate cancer vulnerable to immunotherapy
CRISPR editing turns immune‑cold prostate tumors into immunotherapy targets, sparking a new treatment direction.
8 independently checked trend briefs about this subject, newest first.
headlinez.news detected 8 source-qualified news clusters connected to Prostate Cancer between June 24, 2026 and July 27, 2026. They span 1 newsroom category and average 5.6 independent sources per brief.
This hub includes only briefs supported by at least four sources and passed by the site's verification gate. Raw or weak detections may exist but are excluded here. Topic matching is based on the entities and themes recorded with each brief; open a card to inspect its source links, publication time, verification label and velocity history. Read the methodology and editorial policy for the full rules.
CRISPR editing turns immune‑cold prostate tumors into immunotherapy targets, sparking a new treatment direction.
Medical experts report a rise in prostate cancer diagnoses, emphasizing the role of early detection and robotic surgery in patient outcomes.
New research suggests focal therapy is a viable alternative for prostate cancer, offering similar effectiveness to traditional methods with fewer side effects.
A second PSMA PET scan is influencing treatment paths for nearly half of prostate cancer patients, according to new clinical findings.
Regulatory shifts and medical debates reshape access to testosterone therapy amid aging population concerns
Medical reports highlight a potential shift in prostate cancer screening as new tools emerge to supplement traditional PSA testing.
A new blood test is showing superior results in detecting aggressive prostate cancer compared to standard screening methods.
A new blood test could double prostate cancer detection rates, reshaping early screening